Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
1.
Bone Marrow Transplant ; 52(1): 47-52, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27668766

ABSTRACT

We compared the outcomes of immunosuppressive treatment (IST) with those of alternative donor hematopoietic stem cell transplantation (HSCT) in children and adolescents with severe aplastic anemia (SAA). The medical records of 42 patients with SAA who received frontline IST (N=19) or frontline HSCT with an alternative donor (N=23) between 1998 and 2012 were analyzed retrospectively. Six patients responded in the frontline IST group, whereas 11 underwent salvage HSCT after IST failure. Twenty-one of 23 patients who underwent frontline HSCT survived without treatment failure. The estimated failure-free survival rate of the frontline HSCT group was higher than that of the frontline IST group (91.3% vs 30.7% respectively, P<0.001). Six of 11 patients who underwent salvage HSCT experienced event-free survival (EFS). The estimated EFS of the frontline HSCT group was higher than that of the salvage HSCT group (91.3% vs 50.9% respectively, P=0.015). The outcome of alternative donor HSCT was better than commonly reported rates, especially in patients who underwent frontline HSCT. These results suggest that frontline alternative donor HSCT may be a better treatment option than IST for children and adolescents with SAA who lack a human leukocyte Ag-matched familial donor.


Subject(s)
Anemia, Aplastic/mortality , Anemia, Aplastic/therapy , HLA Antigens , Hematopoietic Stem Cell Transplantation , Immunosuppression Therapy , Unrelated Donors , Adolescent , Age Factors , Allografts , Child , Child, Preschool , Disease-Free Survival , Female , Humans , Infant , Male , Survival Rate
2.
Clin Genet ; 89(2): 222-7, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26451869

ABSTRACT

Familial hemophagocytic lymphohistiocytosis (F-HLH or FHL) is a potentially fatal immune dysregulation syndrome with a heterogeneous genetic background. Most recently, STXBP2 has been identified as the causative gene of type 5 FHL (FHL5) with a worldwide distribution. In this study, we investigated the prevalence of FHL5 in Korea. About 50 Korean pediatric patients with HLH who lacked pathogenic mutations in PRF1, UNC13D, or in STX11 from the previous series of 72 patients with HLH were analyzed for STXBP2 mutations by conventional sequencing analyses. As a result, we found one patient with two novel mutations of STXBP2: c.184A>G and c.577A>C. c.184A>G (p.Asn62Asp) was located within a highly conserved region of the STXBP2 protein and predicted to be deleterious. c.577A>C in exon 7 resulted in incomplete splicing mutation with exon 7 skipping concurrent with exon 7-retained transcript with p.Lys193Gln substitution. The frequency of FHL5 was ~1% (1/72) in Korean pediatric patients with HLH. This is the first study on FHL5 in Korea, and the data from a nationwide patient cohort provide another piece of genetic profiles of FHL.


Subject(s)
Lymphohistiocytosis, Hemophagocytic/epidemiology , Lymphohistiocytosis, Hemophagocytic/genetics , Munc18 Proteins/genetics , Mutation/genetics , Adolescent , Amino Acid Sequence , Base Sequence , Child , Child, Preschool , Female , Humans , Infant , Male , Molecular Sequence Data , Munc18 Proteins/chemistry , Prevalence , Protein Structure, Tertiary , RNA/genetics , Republic of Korea
3.
Transpl Infect Dis ; 16(6): 919-29, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25405808

ABSTRACT

BACKGROUND: Cytomegalovirus (CMV) infection is a major cause of morbidity in allogeneic hematopoietic cell transplant (alloHCT) recipients. Little is known about the epidemiology of antiviral resistance in the pediatric population. We performed the prospective study to assess the impact of drug-resistant CMV infections in pediatric alloHCT recipients. METHODS: Pediatric alloHCT recipients who developed CMV infection were consecutively enrolled from May 2009 to April 2012. CMV polymerase chain reaction amplification and sequencing analysis for UL97 and UL54 genes were performed at enrollment and during follow-up. RESULTS: In total, 208 sequence data from viruses in 49 recipients were eligible for the final analysis. Resistant CMV infection caused by UL97 and UL54 mutations occurred in 4.1% (2/49) and 2.0% (1/49), respectively. Known UL97 mutations, M460V and C592G, were observed in each of 2 patients. One patient with the M460V UL97 mutation had an additional T700A UL54 mutation. Drug-resistant CMV attributable mortality was 2.0% (1/49). One or more known sequence variants (drug-sensitive) were observed in all 49 patients. Thirty-one (63.3%) and 28 patients (60.9%) already had known UL97 and UL54 sequence variants before antiviral therapy, respectively. CONCLUSION: This study provides comprehensive information on the epidemiology of both UL97 and UL54 variants and mutations in alloHCT recipients.


Subject(s)
Antiviral Agents/pharmacology , Cytomegalovirus Infections/virology , Cytomegalovirus/drug effects , Drug Resistance, Viral , Hematopoietic Stem Cell Transplantation , Adolescent , Child , Child, Preschool , Cytomegalovirus/genetics , Female , Genotype , Humans , Infant , Male , Mutation
4.
Vox Sang ; 107(2): 181-7, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24517183

ABSTRACT

BACKGROUND AND OBJECTIVES: Transplantation of cryopreserved umbilical cord blood (UCB) can be used to treat a multitude of haematologic and immunological diseases. In this study, we examined the quality of UCB cryopreserved for 2 (group I), 4 (group II) and 6 (group III) years. METHODS: The following parameters and procedures were used to test individual units of cryopreserved UCB: the number of total nucleated cells (TNC), cell viability, CFU-GM assay, T-cell activation in vitro and haematopoietic stem cell engraftment in NOD/SCID mice in vivo. RESULTS: The TNC recovery rates for groups I, II and III were 106·2 ± 6·17%, 96·69 ± 6·39% and 100·38 ± 5·27%, respectively, and the mean percentages of viable cells after thawing were 86·88%, 86·38% and 87·43%. When TNC were plated at 5 × 10(3), the number of CFU-GM was 13·6 (group I), 13·8 (group II), 14·2 (group III) and 14·7 (fresh UCB). We confirmed that the huCD4(+) and huCD8(+) T cells within cryopreserved UCB are functionally responsive by assessment of activated huCD25(+) cells. Moreover, the percentage of huCD45(+) cells in the bone marrow was 4·32 ± 1·29% (group I), 4·48 ± 1·11% (group II), 4·40% ± 1·12% (group III) and 4·50% ± 0·66% (fresh UCB), and that in the peripheral blood was 14·69 ± 3·08% (group I), 15·24 ± 4·05% (group II), 15·74 ± 3·43% (group III) and 17·48 ± 3·74% (fresh UCB) in NOD/SCID mice infused with isolated huCD34(+) cells. CONCLUSION: These results indicated that cryopreserved UCB units efficiently retrieve in functionally competent form and are suitable for transplantation.


Subject(s)
Cryopreservation , Fetal Blood/cytology , Hematopoietic Stem Cells/physiology , Animals , Cell Survival , Hematopoietic Stem Cell Transplantation , Humans , Mice , Mice, Inbred NOD , Mice, SCID , Quality Control
5.
Bone Marrow Transplant ; 48(8): 1040-5, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23396407

ABSTRACT

Success of umbilical cord blood transplantation (UCBT) has been limited by a high rate of graft failure and delayed hematological recovery. It has been postulated that MSCs have hematopoiesis-supportive properties. Therefore, to overcome the limitation of UCBT, third-party UCB-derived MSCs were co-transplanted in recipients receiving unrelated UCBT. Seven patients received UCB and third-party UCB-MSCs. Hematopoietic recovery and transplantation outcomes were compared with historic controls. There was no acute toxicity associated with the infusion of MSCs. The median day to neutrophil engraftment was 19 days in patients, as compared with 24 days in controls (P=0.03). The median day of platelet engraftment was 47 days and 57 days in patients and controls, respectively (P=0.26). In addition, there was no engraftment failure in the MSC group. The incidence of acute and chronic GVHD was comparable between the two groups. However, veno-occlusive disease and TRM did not occur in the MSC group. Third-party UCB-MSCs infusion was safe and feasible. MSCs may also enhance the engraftment of UCBT and prevent rejection. In addition, MSCs may have a role in decreasing TRM. Randomized, controlled trials are required to confirm these results and longer follow-up will determine the effects of MSCs on the risk of relapse.


Subject(s)
Cord Blood Stem Cell Transplantation/methods , Mesenchymal Stem Cell Transplantation/methods , Acute Disease , Case-Control Studies , Child , Child, Preschool , Cord Blood Stem Cell Transplantation/adverse effects , Female , Graft Rejection/prevention & control , Graft Survival , Graft vs Host Disease/etiology , Graft vs Host Disease/prevention & control , Humans , Leukemia/surgery , Male , Mesenchymal Stem Cell Transplantation/adverse effects , Treatment Outcome
6.
Bone Marrow Transplant ; 48(7): 932-8, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23318534

ABSTRACT

In an effort to improve survival and reduce late adverse effects of radiation therapy (RT), 25 children <3 years of age with malignant brain tumors received tandem high-dose chemotherapy (HDCT) and auto-SCT following six cycles of induction chemotherapy. RT was either not given or deferred until 3 years of age if the patient was in CR after tandem HDCT/auto-SCT. Tumors relapsed or progressed in nine patients (five during induction treatment), and two of these patients survived after receiving salvage treatment, including RT. Two patients died due to toxicities during tandem HDCT/auto-SCT. A total of 16 patients survived to a median follow-up period of 52 months (range 18-96) from the time of diagnosis. Four of these patients did not receive RT, two received local RT (L-RT), three received craniospinal RT (CSRT), and seven received both L-RT and CSRT. The 5-year OS and EFS rates were 67.8±9.4% and 55.5±10.0%, respectively. Neuroendocrine and neurocognitive functions evaluated 3 years after tandem HDCT/auto-SCT were acceptable. Our results indicate that tandem HDCT/auto-SCT may improve survival in young children with malignant brain tumors with an acceptable level of risk of long-term toxicity.


Subject(s)
Brain Neoplasms/therapy , Stem Cell Transplantation , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Autografts , Brain Neoplasms/mortality , Brain Neoplasms/physiopathology , Child, Preschool , Disease-Free Survival , Female , Follow-Up Studies , Humans , Infant , Infant, Newborn , Male , Survival Rate
7.
Bone Marrow Transplant ; 48(1): 68-73, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22635247

ABSTRACT

From January 2004 to December 2008, 50 consecutive patients with high-risk neuroblastoma were assigned to receive tandem HDCT (high-dose chemotherapy)/auto-SCT after nine cycles of induction chemotherapy. CEC (carboplatin + etoposide + cyclophosphamide) regimen and TM (thiotepa + melphalan)-TBI regimen (or TM regimen for stage 3 patients) were the first and second HDCT regimens. Local radiotherapy, differentiation therapy with 13-cis-retinoid acid and immunotherapy with interleukin-2 were given after tandem HDCT/auto-SCT. Of the 50 patients, 49 underwent a first HDCT/auto-SCT and 47 underwent a second HDCT/auto-SCT. The tumor relapsed or progressed in 14 patients, secondary malignancy developed in one patient and one patient died from chronic lung disease. Therefore, 34 patients remained event free with a median follow-up of 54.5 months (range, 14-94 months) from diagnosis. The probabilities of 5-year OS and EFS for all 50 patients were 77.0% (95% confidence interval (CI), 63.7-90.3) and 71.4% (95% CI, 58.7-84.1), respectively. However, all patients who remained event free for >3 years after tandem HDCT/auto-SCT experienced late adverse effects. Chemotherapeutic dose-escalation strategy using tandem HDCT/auto-SCT was very encouraging for survival. However, further studies incorporating newer treatment modalities are needed to reduce late adverse effects without jeopardizing the survival rate.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Induction Chemotherapy , Neuroblastoma/therapy , Radiotherapy/methods , Stem Cell Transplantation , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bone Neoplasms/diagnosis , Bone Neoplasms/pathology , Bone Neoplasms/secondary , Bone Neoplasms/therapy , Child , Child, Preschool , Combined Modality Therapy/adverse effects , DNA Copy Number Variations , Feasibility Studies , Humans , Induction Chemotherapy/adverse effects , Infant , Interleukin-2/administration & dosage , Interleukin-2/adverse effects , Interleukin-2/therapeutic use , Isotretinoin/administration & dosage , Isotretinoin/adverse effects , Isotretinoin/therapeutic use , N-Myc Proto-Oncogene Protein , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Neoplasm Staging , Neuroblastoma/diagnosis , Neuroblastoma/pathology , Neuroblastoma/secondary , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Oncogene Proteins/genetics , Oncogene Proteins/metabolism , Prognosis , Prospective Studies , Radiotherapy/adverse effects , Stem Cell Transplantation/adverse effects , Survival Analysis , Transplantation, Autologous , Whole-Body Irradiation/adverse effects
8.
Vox Sang ; 103(2): 150-8, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22372549

ABSTRACT

BACKGROUND: Overnight (ON) storage of peripheral blood stem cell (PBSC) occurs frequently in clinical settings. However, there are no standard guidelines for optimal storage conditions of freshly harvested PBSC. The aim of this study was to investigate the influence of storage temperatures on the quality of autologous PBSC and establish optimal storage conditions before cryopreservation. METHODS: A retrospective analysis was performed on 260 PBSC harvests according to pre-cryopreservation conditions: immediate processing or ON storage at room temperature (RT). For direct comparison, 30 autologous PBSC products were collected prospectively and prepared under three different pre-cryopreservation conditions: immediate processing, ON storage at 4°C and ON storage at RT. The recovery of CD34(+) cells, post-thaw CFU-GM count and viability were analysed. RESULTS: Retrospective analysis revealed that post-thaw CFU-GM count was significantly lower when PBSC were stored ON at RT compared to when immediately processed (136·4 vs. 409·6/µl). Prospective analysis showed a mean recovery of CD34(+) cells of 65·5 ± 25·1%, 70·5 ± 27·4% and 35·9 ± 25·1% for immediate processing, ON storage at 4°C and ON storage at RT, respectively. Similarly, mean viability and CFU-GM counts were significantly reduced when stored ON at RT compared to when immediately processed or stored ON at 4°C (60·4 ± 25·6 vs. 84·1 ± 12·9 vs. 82·7 ± 12·6%, 15·7 ± 25·7 vs. 398·5 ± 906·2 vs. 350·0 ± 847·9/µl, respectively). CONCLUSIONS: ON storage of autologous PBSC at RT significantly decreased the quality of HPCs. These data indicate that ON storage of autologous PBSC at 4°C would be the most reasonable approach for maintaining the quality of HPCs when immediate processing is not possible.


Subject(s)
Cryopreservation/methods , Hematopoietic Stem Cells/cytology , Peripheral Blood Stem Cell Transplantation , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Male , Neoplasms/therapy , Retrospective Studies , Time Factors , Transplantation, Autologous
10.
Transplant Proc ; 42(7): 2753-8, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20832581

ABSTRACT

Umbilical cord blood (UCB)-derived mesenchymal stem cells (MSC) facilitate the engraftment of human (h) hematopoietic stem cells when transplanted simultaneously in animal and human studies. However, the type of MSCs that preferentially enhance the engraftment of HSCs is unknown. Recent studies have shown that MSCs derived from a single source are heterogeneous in terms of cell size, morphology, proliferation rate, and differentiation potential. This study was designed to investigate the properties of UCB-MSCs, which influence the engraftment of hHSCs in a NOD/SCID mouse model. We categorized MSCs as being the most effective (UCB-352 MSCs) or the least effective (UCB-156 MSCs) at promoting the homing and engraftment of HSCs, and compared the characteristics of these 2 MSC populations. We observed that the 2 populations showed differences in characteristics typical of immature MSCs, and related to proliferation potential. We showed that UCB-352 MSCs, which proliferate quickly, preferentially enhanced the engraftment of HSCs in NOD/SCID mice. In addition, we observed differences in the pattern of both PODXL and Oct4 expression, and in the levels of cytokines such as SDF-1 and SCF using flow cytometry and membrane arrays. The more effective UCB-352 MSCs expressed higher levels of PODXL and Oct4, which were associated with immaturity, than did the UCB-156 MSCs. Furthermore, UCB-352 cells secreted greater levels of SDF-1 and SCF, both of which are required for hematopoiesis. We propose that the proliferation potential of UCB-MSCs, coupled with their immature characteristics, may serve as a novel standard to promote the homing and engraftment of HSCs.


Subject(s)
Hematopoietic Stem Cell Transplantation/methods , Mesenchymal Stem Cells/cytology , Mice, Inbred NOD/surgery , Mice, SCID/surgery , Adenosine Triphosphate/analysis , Animals , Cell Division , Cytokines/analysis , Delivery, Obstetric , Fetal Blood/cytology , Humans , Mesenchymal Stem Cells/physiology , Mice , Transplantation, Heterologous/methods
11.
Bone Marrow Transplant ; 45(8): 1287-93, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20010866

ABSTRACT

Four hundred and sixty-seven hematopoietic stem cell transplantations (HSCTs) (217 autologous and 250 allogeneic HSCT) were performed in 374 children at four pediatric HSCT centers in Korea from January 2005 to December 2007. Among 467 transplants, veno-occlusive disease (VOD) developed in 72 transplants (15.4%) at a median of 10 days after HSCT. Multivariate analysis showed that BU or TBI-containing regimen (P=0.002), VOD prophylaxis without lipo-prostaglandin E1 (PGE1) (P=0.012), number of previous HSCT (P=0.014), and pretransplant serum ferritin (P=0.018) were independent risk factors for developing VOD. Mean serum ferritin levels were significantly higher in HSCT with VOD (2109.6+/-2842.5 ng/ml) than in HSCT without VOD (1315.9+/-1094.4 ng/ml) (P<0.001). The relative risk of death within 100 days of HSCT in transplants with VOD compared with transplants without VOD was 3.39 (confidence interval: 1.78-6.45). Our results suggest that lipo-PGE1 might have a protective effect against the development of VOD, and pretransplant serum ferritin could act as a risk factor for VOD. A larger prospective study is needed to confirm a possible role of lipo-PGE1 and iron chelation therapy in reducing the incidence of VOD.


Subject(s)
Hematopoietic Stem Cell Transplantation/methods , Hepatic Veno-Occlusive Disease/epidemiology , Alprostadil/therapeutic use , Child , Female , Ferritins/blood , Hematopoietic Stem Cell Transplantation/adverse effects , Hepatic Veno-Occlusive Disease/etiology , Humans , Incidence , Iron Chelating Agents/therapeutic use , Korea , Male , Risk Factors , Survival Rate , Treatment Outcome , Vasodilator Agents
12.
Br J Ophthalmol ; 92(9): 1180-4, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18650212

ABSTRACT

BACKGROUND/AIMS: To analyse the clinical manifestations and results of treatment for patients with retinoblastoma in Korea. METHODS: The medical records of 70 children (92 eyes) diagnosed as having retinoblastoma and treated between 2000 and 2006 were retrospectively analysed. Data on gender, age at diagnosis, laterality, presenting sign, classification of tumour, treatment modality and prognosis were collected. RESULTS: The most common presenting sign was leucocoria (80%). 31.4% developed bilateral retinoblastoma. Using the International Classification of Retinoblastoma, 7.5% were group A, 23.8% were group B, 6.3% were group C, 38.8% were group D, and 23.8% were group E. 26.1% of eyes were treated with chemoreduction and/or focal therapy, namely, they achieved globe preservation, and all other eyes were enucleated. The globe preservation was achieved in 100% of group A, 77.8% of group B, 66.7% of group C, and 26.7% of group D. CONCLUSIONS: In Korea, most children with retinoblastoma showed an advanced stage of tumour at the time of diagnosis and although they were treated with an updated therapeutic approach according to the newly introduced classification, the rate of globe preservation did not reach that of developed countries. Increased surveillance should be performed.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Eye Enucleation , Retinal Neoplasms , Retinoblastoma , Carboplatin/administration & dosage , Child , Child, Preschool , Etoposide/administration & dosage , Eye/pathology , Female , Humans , Infant , Korea , Male , Neoplasm Recurrence, Local/prevention & control , Retinal Neoplasms/diagnosis , Retinal Neoplasms/drug therapy , Retinal Neoplasms/surgery , Retinoblastoma/diagnosis , Retinoblastoma/drug therapy , Retinoblastoma/surgery , Retrospective Studies , Treatment Outcome , Vincristine/administration & dosage
13.
Bone Marrow Transplant ; 42(6): 385-91, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18574441

ABSTRACT

Although external-beam radiation therapy (EBRT) has been an effective treatment modality in patients with bilateral advanced retinoblastoma, it significantly increases the risk of second malignancies and facial deformities. This study aimed to evaluate the efficacy of tandem high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) for treatment, instead of EBRT, in children with bilateral advanced retinoblastoma. Fourteen patients with bilateral retinoblastoma received chemotherapy, and local therapy was provided whenever possible. When at least one functional eye could not be saved by chemoreduction and local therapy, tandem HDCT/ASCR was provided to avoid EBRT. As a result, nine patients received tandem HDCT/ASCR. The toxicities were tolerable and there was no TRM. All nine patients who received tandem HDCT/ASCR had at least one functional eye without EBRT, and in two patients, both eyes were saved. No second malignancy has developed to date. HDCT/ASCR might be an effective treatment for bilateral advanced retinoblastoma, especially in cases in which at least one functional eye could not be preserved with chemoreduction and local therapy alone, and where EBRT was unavoidable. Long-term follow-up and further studies are needed to evaluate the efficacy and toxicity of HDCT/ASCR as an alternative treatment to EBRT.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Peripheral Blood Stem Cell Transplantation , Retinoblastoma/therapy , Adolescent , Adult , Child , Child, Preschool , Female , Humans , Male , Retrospective Studies , Transplantation, Autologous
14.
Bone Marrow Transplant ; 40(1): 37-45, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17468771

ABSTRACT

From June 1997 to August 2005, 52 consecutive newly diagnosed stage 4 neuroblastoma patients over 1 year of age were assigned to receive tandem high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) as consolidation therapy. Fifty of the 52 patients underwent a first HDCT/ASCR and 44 patients underwent a second HDCT/ASCR. Eight patients (15.4%) died from treatment-related toxicity (seven during the second HDCT/ASCR). Total body irradiation (TBI) in the first HDCT/ASCR and a shorter interval (< 12 weeks) between the first and second HDCT/ASCR were associated with a higher rate of treatment-related death in the second HDCT/ASCR (P = 0.032 and 0.095, respectively). The tumor relapsed or progressed in 11 patients, and 33 patients remained event free with a median follow-up of 53 months (range 19-117) from diagnosis. The 5-year event-free survival (EFS) (+/- 95% confidence interval) for all 52 patients was 62.1+/-13.7%. The application of TBI and local radiotherapy, and a longer interval between the first and second HDCT/ASCR were independently associated with a better EFS (P = 0.026, 0.007 and 0.020, respectively). However, further studies will be needed to decrease the toxic death rate in the second HDCT/ASCR while reducing the relapse rate.


Subject(s)
Antineoplastic Agents/therapeutic use , Brain Neoplasms/drug therapy , Brain Neoplasms/therapy , Neuroblastoma/drug therapy , Neuroblastoma/therapy , Brain Neoplasms/mortality , Brain Neoplasms/pathology , Combined Modality Therapy , Humans , Immunotherapy , Infant , Interleukin-2/therapeutic use , Neoplasm Staging , Neuroblastoma/mortality , Neuroblastoma/pathology , Retrospective Studies , Survival Rate , Transplantation Conditioning , Transplantation, Autologous , Treatment Outcome , Tretinoin/therapeutic use , Whole-Body Irradiation
15.
Bone Marrow Transplant ; 39(9): 515-21, 2007 May.
Article in English | MEDLINE | ID: mdl-17334379

ABSTRACT

We retrospectively reviewed the engraftment kinetics following unrelated cord blood transplantation (CBT) in association with the post-thaw colony-forming units-granulocyte/macrophage (CFU-GM) number along with the numbers of total nucleated cells (TNC), CD34(+) cells and CD3(+) cells. A total of 71 cord blood units prepared for 53 patients (double-unit CBT in 18 patients) were evaluated. Either the number of infused CFU-GM or CD34(+) cells was significantly lower in patients who failed to achieve engraftment (P=0.028 and 0.005, respectively). Post-thaw CFU-GM, TNC and CD34(+) cells correlated with the speed of neutrophil engraftment (P=0.004, 0.037 and 0.004, respectively), whereas only CFU-GM showed a significant correlation with platelet engraftment (r=-0.385, P=0.024). In double-unit transplants, the number of CFU-GM was the only significant factor predicting engraftment of the predominating unit (P=0.006). We conclude that the post-thaw CFU-GM number is a reliable predictor of rapid engraftment after CBT as well as of the predominating unit in double-unit transplants. Thus, it would be important to perform post-thaw CFU-GM assay on cryopreserved aliquots from several candidate cord blood units in advance before CBT to avoid selecting the unit that might possess a low clonogenic potential.


Subject(s)
Colony-Forming Units Assay , Cord Blood Stem Cell Transplantation , Cryopreservation , Graft Survival , Granulocyte Precursor Cells , Adolescent , Antigens, CD34 , Child , Child, Preschool , Humans , Infant , Male , Predictive Value of Tests , Retrospective Studies , Transplantation, Homologous
16.
J Clin Pharm Ther ; 32(2): 199-202, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17381671

ABSTRACT

OBJECTIVE: To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl. CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. Based on the Naranjo probability scale, serotonin syndrome was a probable adverse reaction associated with co-administration of citalopram and fentanyl. DISCUSSION: Serotonin syndrome is a potentially lethal pharmacodynamic interaction between medications that increase serotonergic transmission at the synaptic junction. The development of new pharmacological agents with varied properties and actions has increased the risk of serotonin syndrome as a clinical diagnosis. SSRIs and fentanyl are commonly co-administered, especially in the setting of chronic or malignant pain, as underlying depression may contribute to the pathogenesis of pain. CONCLUSION: Healthcare professionals should be aware of the possible development of serotonin syndrome as a complication of initiation of fentanyl and other phenylpiperidine opioids in patients treated with SSRIs.


Subject(s)
Citalopram/adverse effects , Drug Interactions , Fentanyl/adverse effects , Serotonin Syndrome/chemically induced , Aged , Citalopram/therapeutic use , Drug Therapy, Combination , Fentanyl/therapeutic use , Humans , Myelodysplastic Syndromes/drug therapy , Myeloproliferative Disorders/drug therapy , Serotonin Syndrome/diagnosis , Selective Serotonin Reuptake Inhibitors/adverse effects , Selective Serotonin Reuptake Inhibitors/therapeutic use
17.
Bone Marrow Transplant ; 38(1): 29-35, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16715103

ABSTRACT

We studied the administration method during a transition period from continuous intravenous (i.v.) infusion to oral administration of cyclosporin A (CsA). Thirty-two pediatric hematopoietic stem cell transplant (HSCT) recipients, between the ages of 8 months and 15.6 years (median 7.1 years) participated in this study. The pharmacokinetic properties of CsA was evaluated during the transition period from i.v. to oral CsA. The daily oral dose of CsA was three times higher than the i.v. dose. Oral dosing began immediately after the continuous infusion was discontinued. Whole-blood CsA concentrations were measured by a monoclonal fluorescence polarization immunoassay (FPIA). The mean+/-s.d. value of bioavailability (F), maximum concentration (C(max)), half-life (t(1/2)) of CsA were 43.1+/-14.4%, 1135.3+/-340.6 ng/ml and 3.1+/-1.2 h, respectively. Mean clearance (CL)+/-s.d. was 480.9+/-103.7, 414.9+/-137.1 and 320+/-51.8 ml/h/kg in patients <20, 20-40 and >40 kg of body weight, respectively. The CsA CL of younger children was significantly greater than for older children (P=0.044). CsA trough levels were maintained within the therapeutic range throughout the transition period. Therefore, our findings suggest that the immediate administration of an oral formulation, after discontinuation of the continuous infusion, would be practical and effective for routine clinical use.


Subject(s)
Anemia, Aplastic/therapy , Cyclosporine/administration & dosage , Graft vs Host Disease/therapy , Hematopoietic Stem Cell Transplantation , Leukemia/therapy , Administration, Oral , Adolescent , Age Factors , Anemia, Aplastic/diagnosis , Biological Availability , Body Weight , Child , Child, Preschool , Cyclosporine/analysis , Cyclosporine/pharmacokinetics , Female , Graft vs Host Disease/diagnosis , Humans , Infant , Infusions, Intravenous , Leukemia/diagnosis , Male , Metabolic Clearance Rate , Time Factors , Treatment Outcome
18.
Neuroscience ; 133(4): 1007-19, 2005.
Article in English | MEDLINE | ID: mdl-15964489

ABSTRACT

The action of riluzole, a neuroprotective drug, on cloned delayed rectifier K+ channels (Kv1.5 and Kv3.1) was examined using the whole-cell patch-clamp technique. Riluzole reversibly inhibited Kv1.5 currents in a concentration-dependent manner with an IC50 of 39.69+/-2.37 microM. G-protein inhibitors (pertussis toxin and GDPbetaS) did not prevent this inhibition of riluzole on Kv1.5. No voltage-dependent inhibition by riluzole was found over the voltage range in which channels are fully activated. Riluzole shifted the steady-state inactivation curves of Kv1.5 in a hyperpolarizing direction in a concentration-dependent manner. It accelerated the deactivation kinetics of Kv1.5 in a concentration dependent-manner, but had no effect on the steady-state activation curve. Riluzole exhibited a use-independent inhibition of Kv1.5. The effects of riluzole on Kv3.1, the Shaw-type K+ channel were also examined. Riluzole caused a concentration-dependent inhibition of Kv3.1 currents with an IC50 of 120.98+/-9.74 microM and also shifted the steady-state inactivation curve of Kv3.1 in the hyperpolarizing direction. Thus, riluzole inhibits both Kv1.5 and Kv3.1 currents in a concentration-dependent manner and interacts directly with Kv1.5 by preferentially binding to the inactivated and to the closed states of the channel.


Subject(s)
Membrane Potentials/drug effects , Neural Inhibition/drug effects , Neuropeptides/physiology , Neuroprotective Agents/pharmacology , Potassium Channels, Voltage-Gated/physiology , Riluzole/pharmacology , Animals , CHO Cells , Cricetinae , Dose-Response Relationship, Drug , Dose-Response Relationship, Radiation , Drug Interactions , Electric Stimulation/methods , Guanosine Diphosphate/analogs & derivatives , Guanosine Diphosphate/pharmacology , Inhibitory Concentration 50 , Kinetics , Kv1.5 Potassium Channel , Membrane Potentials/physiology , Membrane Potentials/radiation effects , Patch-Clamp Techniques/methods , Pertussis Toxin/pharmacology , Shaw Potassium Channels , Thionucleotides/pharmacology
19.
Bone Marrow Transplant ; 31(6): 447-52, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12665839

ABSTRACT

In total, 18 of 26 double high-dose chemotherapies (HDCT) in pediatric solid tumors were rescued with peripheral blood stem cells collected during a single leukapheresis round (single-harvest group, SHG). In the remaining eight HDCT, additional leukapheresis were necessary after the first HDCT (HDCT1) to rescue the second HDCT (HDCT2) (double-harvest group, DHG). Stem cell collection after HDCT1 was inefficient and delayed in patients who had received prior chemotherapy before HDCT1. The interval between HDCT1 and HDCT2 was shorter in SHG than in DHG (median 62.5 days vs 178.5 days, P-value=0.002). Hematologic recovery in HDCT2 was delayed compared to HDCT1. However, there was no difference in hematologic recovery between SHG and DHG. A high rate of treatment-related mortality (TRM) was recorded during HDCT2, but there was no evidence that the shorter interval caused a higher rate of TRM (P-value=0.454). The probability of disease-free survival at 2 years after HDCT2 in the SHG and DHG were 66.7 and 25.0%, respectively (P-value=0.031). Therefore, to administer the second HDCT earlier in double HDCT, and thus to improve the survival of patients with high-risk solid tumors, the single-harvest approach is recommended rather than the double-harvest approach.


Subject(s)
Antineoplastic Agents/administration & dosage , Hematopoietic Stem Cell Transplantation , Leukapheresis , Nervous System Neoplasms/drug therapy , Neuroblastoma/drug therapy , Adolescent , Adult , Aged , Blood Platelets/cytology , Brain Neoplasms/drug therapy , Brain Neoplasms/mortality , Cerebellar Neoplasms/drug therapy , Cerebellar Neoplasms/mortality , Combined Modality Therapy , Female , Glioma/drug therapy , Glioma/mortality , Humans , Male , Medulloblastoma/drug therapy , Medulloblastoma/mortality , Middle Aged , Nervous System Neoplasms/mortality , Neuroblastoma/mortality , Risk Factors , Survival Rate , Transplantation, Autologous , Treatment Outcome
20.
J Neurophysiol ; 86(5): 2405-12, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11698530

ABSTRACT

Activation of metabotropic glutamate receptors (mGluRs), which are coupled to G proteins, has important roles in certain forms of synaptic plasticity including corticostriatal long-term depression (LTD). In the present study, extracellular field potential and whole cell voltage-clamp recording techniques were used to investigate the effect of mGluR antagonists with different subtype specificity on high-frequency stimulation (HFS)-induced LTD of synaptic transmission in the striatum of brain slices obtained from 15-to 25-day-old rats. Induction of LTD was prevented during exposure to the nonselective mGluR antagonist (RS)-alpha-methyl-4-carboxyphenylglycine (500 microM). The group I mGluR-selective antagonists (S)-4-carboxy-phenylglycine (50 microM) and (RS)-1-aminoindan-1,5-dicarboxylic acid (100 microM) prevented induction of LTD when applied before and during HFS. The mGluR1-selective antagonist 7-(Hydroxyimino) cyclopropa[b]chromen-1a-carboxylate ethyl ester (80 microM) also blocked LTD induction. Unexpectedly, the mGluR5-selective antagonist 2-methyl-6-(phenylethyl)-pyridine (10 microM) also prevented LTD induction. The group II mGluR antagonist LY307452 (10 microM) did not block LTD induction at corticostriatal synapses, but LY307452 was able to block transient synaptic depression induced by the group II agonist LY314593. None of the antagonists had any effect on basal synaptic transmission at the concentrations used, and mGluR antagonists did not reverse LTD when applied beginning 20 min after HFS. These results suggest that both group I mGluR subtypes contribute to the induction of LTD at corticostriatal synapses.


Subject(s)
Corpus Striatum/physiology , Long-Term Potentiation/physiology , Receptors, Metabotropic Glutamate/physiology , Synapses/physiology , Action Potentials , Animals , Corpus Striatum/drug effects , Electric Stimulation/methods , Excitatory Amino Acid Agonists/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , In Vitro Techniques , Long-Term Potentiation/drug effects , Patch-Clamp Techniques , Rats , Rats, Sprague-Dawley , Receptors, Metabotropic Glutamate/antagonists & inhibitors , Synaptic Transmission/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...